DexCom/DXCM

$130.39

-2.91%
-
1D1W1MYTD1YMAX

About DexCom

DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.

Ticker

DXCM

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Kevin Sayer

Employees

9,600

Headquarters

San diego, United States

DexCom Metrics

BasicAdvanced
$51.61B
Market cap
104.41
P/E ratio
$1.28
EPS
1.21
Beta
-
Dividend rate
$51.61B
1.20822
$142.00
$74.75
3.07M
2.844
2.485
120.507
120.507
104.652
9.29%
25.78%
13.11%
104.414
14.247
24.939
27.034
100.811
24.49%
60.08%
23.42%
-0.9%

What the Analysts think about DexCom

Analyst Ratings

Majority rating from 24 analysts.
Buy

Price Targets

Average projection from 22 analysts.
16.05% upside
High $170.00
Low $122.00
$130.39
Current price
$151.32
Average price target

DexCom Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
24.77% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.03B
6.1%
Net income
$256.3M
112.34%
Profit margin
24.77%
100.24%

DexCom Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.87%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.17
$0.34
$0.50
$0.50
-
Expected
$0.15
$0.23
$0.34
$0.43
$0.27
Surprise
16.09%
50.3%
46.74%
15.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for DexCom stock?

DexCom (DXCM) has a market cap of $51.61B as of April 20, 2024.

What is the P/E ratio for DexCom stock?

The price to earnings (P/E) ratio for DexCom (DXCM) stock is 104.41 as of April 20, 2024.

Does DexCom stock pay dividends?

No, DexCom (DXCM) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next DexCom dividend payment date?

DexCom (DXCM) stock does not pay dividends to its shareholders.

What is the beta indicator for DexCom?

DexCom (DXCM) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the DexCom stock price target?

The target price for DexCom (DXCM) stock is $151.32, which is 15.77% above the current price of $130.71. This is an average based on projections from 22 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell DexCom stock

Buy or sell DexCom stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing